Correspondence on 'Factors associated with progression to inflammatory arthritis in first-degree relatives of individuals with RA following autoantibody positive screening in a non-clinical setting
We have read with great interest the work of Bemis et al studying the factors associated with the progression to inflammatory arthritis (IA) in high-risk immune-positive individuals.1 In their work, the authors longitudinally followed patients at very high risk of developing IA since they cumulated a first-degree relative with rheumatoid arthritis (RA) and the presence of at least one autoantibody associated with RA: rheumatoid factor and/or anticyclic-citrullinated peptide antibodies (ACPA). They confirmed earlier studies showing that high titres of ACPA may predict the development to IA.2 Unexpectedly and in opposition t...
Source: Annals of the Rheumatic Diseases - October 12, 2023 Category: Rheumatology Authors: Scherlinger, M., Schaeverbeke, T. Tags: ARD Correspondence Source Type: research
Rare mimicker of sacroiliitis
A 62-year-old woman was referred for suspected sacroiliitis discovered incidentally on a CT scan performed for pre-transplant assessment, in a context of chronic renal failure due to nephroangiosclerosis with haemodialysis for 18 months. Her renal disease was complicated by anaemia and secondary hyperparathyroidism. She was completely asymptomatic, including no lumbar or buttock pain. The CT scan (figure 1) showed bilateral and symmetrical subchondral bone resorption of blurred appearance responsible for a pseudo-widening which mainly concerned the iliac side, accompanied by an external border of reactive bone condensation...
Source: Annals of the Rheumatic Diseases - September 19, 2023 Category: Rheumatology Authors: Fakih, O., Balblanc, J.-C., Lohse, A. Tags: ARD, Images in rheumatology Source Type: research
Outcomes following SARS-CoV-2 infection in individuals with and without inflammatory rheumatic diseases: a Danish nationwide cohort study
Conclusion
Patients with IRD have a risk of SARS-CoV-2, which nearly corresponds to the general population but had a substantial increased risk of hospitalisation with COVID-19, severe COVID-19, requiring assisted ventilation and COVID-19 leading to death, especially in patients with comorbidities. (Source: Annals of the Rheumatic Diseases)
Source: Annals of the Rheumatic Diseases - September 19, 2023 Category: Rheumatology Authors: Svensson, A. L. L., Emborg, H.-D., Bartels, L. E., Ellingsen, T., Adelsten, T., Cordtz, R., Dreyer, L., Obel, N. Tags: ARD, COVID-19, Epidemiology Source Type: research
Single-cell transcriptome analysis profiles cellular and molecular alterations in submandibular gland and blood in IgG4-related disease
Conclusion
Our data revealed the cellular and molecular changes at the single-cell resolution of IgG4-RD and provide valuable insights into the aetiology and novel therapeutic targets of the autoimmune disease. (Source: Annals of the Rheumatic Diseases)
Source: Annals of the Rheumatic Diseases - September 19, 2023 Category: Rheumatology Authors: Li, Y., Wang, Z., Han, F., Zhang, M., Yang, T., Chen, M., Du, J., Wang, Y., Zhu, L., Hou, H., Chang, Y., Han, L., Lyu, X., Zhang, N., Sun, W., Cai, Z., Wei, W. Tags: ARD, IgG4 related disease Source Type: research
Incidence of primary large vessel vasculitis in Norfolk, UK from 2011 to 2020
Conclusions
This is the first study that reports the incidence of objectively verified primary LVV in the adult population. The incidence of GCA may be affected by the availability of diagnostic pathways. The use of the 2022 classification criteria results in a rise in the classification of GCA and fall in that of TAK. (Source: Annals of the Rheumatic Diseases)
Source: Annals of the Rheumatic Diseases - September 19, 2023 Category: Rheumatology Authors: Mukhtyar, C. B., Beadsmoore, C., Coath, F. L., Ducker, G., Fordham, S., Sisson, K., Yong, C. Y., Watts, R. A. Tags: ARD, Vasculitis Source Type: research
SGLT2 inhibitors alleviated podocyte damage in lupus nephritis by decreasing inflammation and enhancing autophagy
Conclusion
This study confirmed the renoprotective effect of SGLT2 inhibitors in lupus mice, providing more evidence for non-immunosuppressive therapies to improve renal function in classic autoimmune kidney diseases such as LN. (Source: Annals of the Rheumatic Diseases)
Source: Annals of the Rheumatic Diseases - September 19, 2023 Category: Rheumatology Authors: Zhao, X.-y., Li, S.-s., He, Y.-x., Yan, L.-j., Lv, F., Liang, Q.-m., Gan, Y.-h., Han, L.-p., Xu, H.-d., Li, Y.-c., Qi, Y.-y. Tags: ARD, Systemic Lupus erythematosus Source Type: research
Longitudinal gut microbiome analyses and blooms of pathogenic strains during lupus disease flares
Conclusions
Our findings rationalise how blooms of the RG pathobiont may be common drivers of clinical flares of often remitting-relapsing lupus disease, and highlight the potential pathogenic properties of specific strains isolated from active LN patients. (Source: Annals of the Rheumatic Diseases)
Source: Annals of the Rheumatic Diseases - September 19, 2023 Category: Rheumatology Authors: Azzouz, D. F., Chen, Z., Izmirly, P. M., Chen, L. A., Li, Z., Zhang, C., Mieles, D., Trujillo, K., Heguy, A., Pironti, A., Putzel, G. G., Schwudke, D., Fenyo, D., Buyon, J. P., Alekseyenko, A. V., Gisch, N., Silverman, G. J. Tags: Open access, ARD, Systemic Lupus erythematosus Source Type: research
Three-month tapering and discontinuation of long- term, low-dose glucocorticoids in senior patients with rheumatoid arthritis is feasible and safe: placebo-controlled double blind tapering after the GLORIA trial
Conclusions
Tapering prednisolone moderately increases disease activity to the levels of the placebo group (mean still at low disease activity levels) and numerically increases the risk of flare without evidence for adrenal insufficiency. This suggests that withdrawal of low-dose prednisolone is feasible and safe after 2 years of administration. (Source: Annals of the Rheumatic Diseases)
Source: Annals of the Rheumatic Diseases - September 19, 2023 Category: Rheumatology Authors: Almayali, A. A. H., Boers, M., Hartman, L., Opris, D., Bos, R., Kok, M. R., Da Silva, J. A., Griep, E., Klaasen, R., Allaart, C. F., Baudoin, P., Raterman, H. G., Szekanecz, Z., Buttgereit, F., Masaryk, P., Lems, W., Smulders, Y., Cutolo, M., ter Wee, M. Tags: ARD, Rheumatoid arthritis Source Type: research
Cost-utility analysis of tapering strategies of biologicals in rheumatoid arthritis patients in the Netherlands
Conclusions
Based on these analyses, the 50% tapering approach saved the highest cost per QALY lost. (Source: Annals of the Rheumatic Diseases)
Source: Annals of the Rheumatic Diseases - September 19, 2023 Category: Rheumatology Authors: van Esveld, L., Cox, J. M., Kuijper, T. M., Bosch, T. M., Weel-Koenders, A. E. Tags: ARD, Rheumatoid arthritis Source Type: research
Certolizumab pegol, abatacept, tocilizumab or active conventional treatment in early rheumatoid arthritis: 48-week clinical and radiographic results of the investigator-initiated randomised controlled NORD-STAR trial
Conclusions
Compared with active conventional therapy, clinical remission rates were superior for abatacept and certolizumab pegol, but not for tocilizumab. Radiographic progression was low and similar between treatments.
Trial registration number
NCT01491815. (Source: Annals of the Rheumatic Diseases)
Source: Annals of the Rheumatic Diseases - September 19, 2023 Category: Rheumatology Authors: Ostergaard, M., van Vollenhoven, R. F., Rudin, A., Hetland, M. L., Heiberg, M. S., Nordström, D. C., Nurmohamed, M. T., Gudbjornsson, B., Ornbjerg, L. M., Boyesen, P., Lend, K., Horslev-Petersen, K., Uhlig, T., Sokka, T., Grondal, G., Krabbe, S., Tags: Editor's choice, ARD, Rheumatoid arthritis Source Type: research
The 2022 EULAR/ACR points to consider at the early stages of diagnosis and management of suspected haemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS)
Conclusion
These 2022 EULAR/American College of Rheumatology points to consider provide up-to-date guidance, based on the best available published data and expert opinion. They are meant to help guide the initial evaluation, management and monitoring of patients with HLH/MAS in order to halt disease progression and prevent life-threatening immunopathology. (Source: Annals of the Rheumatic Diseases)
Source: Annals of the Rheumatic Diseases - September 19, 2023 Category: Rheumatology Authors: Shakoory, B., Geerlinks, A., Wilejto, M., Kernan, K., Hines, M., Romano, M., Piskin, D., Ravelli, A., Sinha, R., Aletaha, D., Allen, C., Bassiri, H., Behrens, E. M., Carcillo, J., Carl, L., Chatham, W., Cohen, J. I., Cron, R. Q., Drewniak, E., Grom, A. A. Tags: ARD, EULAR papers Recommendation Source Type: research
2023 ACR/EULAR antiphospholipid syndrome classification criteria
Conclusion
These new ACR/EULAR APS classification criteria were developed using rigorous methodology with multidisciplinary international input. Hierarchically clustered, weighted, and risk-stratified criteria reflect the current thinking about APS, providing high specificity and a strong foundation for future APS research. (Source: Annals of the Rheumatic Diseases)
Source: Annals of the Rheumatic Diseases - September 19, 2023 Category: Rheumatology Authors: Barbhaiya, M., Zuily, S., Naden, R., Hendry, A., Manneville, F., Amigo, M.-C., Amoura, Z., Andrade, D., Andreoli, L., Artim-Esen, B., Atsumi, T., Avcin, T., Belmont, M. H., Bertolaccini, M. L., Branch, D. W., Carvalheiras, G., Casini, A., Cervera, R., Coh Tags: ARD, EULAR papers Criteria Source Type: research
The 2023 ACR/EULAR classification criteria for calcium pyrophosphate deposition disease
Conclusion
The 2023 ACR/EULAR CPPD disease classification criteria have excellent performance characteristics and will facilitate research in this field. (Source: Annals of the Rheumatic Diseases)
Source: Annals of the Rheumatic Diseases - September 19, 2023 Category: Rheumatology Authors: Abhishek, A., Tedeschi, S. K., Pascart, T., Latourte, A., Dalbeth, N., Neogi, T., Fuller, A., Rosenthal, A., Becce, F., Bardin, T., Ea, H.-K., Filippou, G., Fitzgerald, J., Iagnocco, A., Liote, F., McCarthy, G. M., Ramonda, R., Richette, P., Sivera, F., A Tags: ARD, EULAR papers Criteria Source Type: research
Annals of the Rheumatic Diseases collection on autoantibodies in the rheumatic diseases: new insights into pathogenesis and the development of novel biomarkers
The rheumatic diseases are a diverse group of conditions that can display autoantibody production, functional immune disturbances and systemic disease manifestations. These autoantibodies can serve as markers for classification, diagnosis, prognosis and disease activity. Among specificities prominently expressed by patients, those directed to nuclear antigens (antinuclear antibodies or ANAs) are markers for specific rheumatic diseases. ANAs can bind to DNA, RNA and complexes of proteins with nucleic acids. Other autoantibodies expressed in the rheumatic diseases are directed to proteins, including IgG, post-translational m...
Source: Annals of the Rheumatic Diseases - September 19, 2023 Category: Rheumatology Authors: Pisetsky, D. S. Tags: ARD Reviews Source Type: research
Correction: Combined therapy of prednisone and mTOR inhibitor sirolimus for treating retroperitoneal fibrosis
Gao H, Liu S, Mai Y, et al. Combined therapy of prednisone and mTOR inhibitor sirolimus for treating retroperitoneal fibrosis. Ann Rheum Dis 2023;82:688-697.
Figure 4 is incorrect and contains the following labeling errors in sub-figures E and F:
cr(mmlol/L), eGFR (mL/min)
The correct version should read: Scr(μmlol/L), eGFR (ml/min/1.73 m2)
Figure 4
doi:10.1136/ard-2022-223736 (Source: Annals of the Rheumatic Diseases)
Source: Annals of the Rheumatic Diseases - September 19, 2023 Category: Rheumatology Tags: Open access, ARD Correction Source Type: research
